1
Egbertson Melissa S, Hartman George D, Halczenko Wasyl, Laswell William L: Novel fibrinogen receptor antagonists.. Merck & Co, April 1, 1992: EP0478328-A1 (101 worldwide citation)

A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.


2
Egbertson Melissa S, Laswell William L, Hartman George D, Duggan Mark E, Halczenko Wasyl: Novel sulfonamide fibrinogen receptor antagonists.. Merck & Co, April 1, 1992: EP0478363-A2 (75 worldwide citation)

A series of non-peptide derivatives of generic formula I that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation. i


3
Birchenough Laura A, Egbertson Melissa, Hartman George D, Turchi Laura M: Fibrinogen receptor antagonists.. Merck & Co, May 5, 1993: EP0540334-A1 (63 worldwide citation)

Fibrinogen receptor antagonists of the formula: are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets. wherein G is:


4
Duggan Mark E, Hartman George D, Ihle Nathan: Fibrinogen receptor antagonists.. Merck & Co, November 11, 1992: EP0512829-A1 (41 worldwide citation)

Fibrinogen receptor antagonists of the formula: are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.


5
Buser Doepner Carolyn A, Coleman Paul J, Cox Christopher D, Fraley Mark E, Garbaccio Robert M, Hartman George D, Heimbrook David C, Kuo Lawrence C, Huber Hans E, Sardana Vinod V, Torrent Maricel, Yan Youwei: Mitotic kinesin binding site. Merck & Co, Buser Doepner Carolyn A, Coleman Paul J, Cox Christopher D, Fraley Mark E, Garbaccio Robert M, Hartman George D, Heimbrook David C, Kuo Lawrence C, Huber Hans E, Sardana Vinod V, Torrent Maricel, Yan Youwei, KOHLI Vineet, January 15, 2004: WO/2004/004652 (41 worldwide citation)

The present invention is directed to the identification, characterization and three-dimensional structure of a novel ligand binding site of KSP. Binding of ligands to the novel binding site result in a conformational change in the three-dimensional structure of the protein and a modulation of the ac ...


6
Egbertson Melissa S, Gould Robert J, Hartman George D: Inhibiting osteoclast-mediated bone resorption using substituted phenyl derivatives.. Merck & Co, February 24, 1993: EP0528587-A1 (28 worldwide citation)

Compounds of the general formula Y is an integer of from 0 to 6 is chosen from: 0, SO2, -CONH-, -NHCO-, -CH2- or R is substituted or unsubstituted mono- or polycyclic saturated hetero-cyclic ring system having 1, 2 or 3 heteroatoms where said heteroatoms are independently chosen from N, O and S and ...


7
Egbertson Melissa S, Gould Robert J, Hartman George D: Inhibiting osteoclast-mediated bone resorption using aminoalkyl-substituted phenyl derivatives.. Merck & Co, February 24, 1993: EP0528586-A1 (22 worldwide citation)

Compounds of the general formula and the pharmaceutically acceptable salts thereof wherein n is an integer of from 0 to 6; Y is CH2, O, SO2, -CONH-, -NHCO-, or R and R are independently hydrogen, C1-8 alkyl, heterocyclyl C0-4 alkyl, aryl C0-4 alkyl, amino C1-4 alkyl, C1-4 alkylamino C1-4 alkyl, or C ...


8
Hartman George D, Hoffman Jacob M, Smith Anthony M, Tucker Thomas J: Kinase inhibitors. Merck & Co, Hartman George D, Hoffman Jacob M, Smith Anthony M, Tucker Thomas J, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, May 21, 2004: WO/2004/041164 (17 worldwide citation)

The present invention relates to compounds which inhibit, regulate and/or modulate kinase signal transduction, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age rel ...


9
Bergman Jeffrey M, Coleman Paul J, Cox Christopher, Hartman George D, Lindsley Craig, Mercer Swati Pal, Roecker Anthony J, Whitman David B: Proline bis-amide orexin receptor antagonists. Merck & Co, Bergman Jeffrey M, Coleman Paul J, Cox Christopher, Hartman George D, Lindsley Craig, Mercer Swati Pal, Roecker Anthony J, Whitman David B, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, November 30, 2006: WO/2006/127550 (17 worldwide citation)

The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceuti ...


10
Arrington Kenneth L, Fraley Mark E, Hartman George D: Mitotic kinesin inhibitors. Merck & Co, Arrington Kenneth L, Fraley Mark E, Hartman George D, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, July 21, 2005: WO/2005/065183 (13 worldwide citation)

The present invention relates to 2,3-diarylquinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and ...